Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
Approximately 40 participants with locally advanced or metastatic melanoma will be enrolled
in 20 sites in the United States into 1 of the following 2 arms: Primary resistance to
initial checkpoint inhibitor (CPI) therapy in Arm A and Acquired resistance to initial CPI
therapy in Arm B. Participants who have disease progression (PD) after discontinuation of
CPIs, especially in neoadjuvant or adjuvant therapy, will be considered to have acquired
resistance in this study. Participants will receive study treatment (Selinexor and
Pembrolizumab) until PD, intolerable toxicity or withdrawal from the study, whichever occurs
first.